• Sadaf Durrani Institute of Chemical Sciences, University of Peshawar
  • Jasmin Shah
  • Mudassir Ahmad Khan
  • Muhammad Rasul Jan


Background: Cerebro-vascular disease is a commonest long term complication of type-2 diabetes mellitus. The study was done to determine concentration of serum adiponectin and lipid profile in type-2 diabetic men with coronary heart disease (CHD) in the region of Khyber Pakhtunkhwa (KPK), and to find possible relationship between them. Methods: This was a cross-sectional study comprising of randomly selected thirty six healthy adult males and thirty six type-2 diabetic males with coronary heart disease. Their fasting blood samples were analysed for serum adiponectin, fasting blood glucose, glycosylated haemoglobin and lipid profile which included total cholesterol (T-C), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C). The relationship of adiponectin with other variables in type-2 diabetic men with coronary heart disease was determined with Pearson correlations coefficient (r). Results: Type-2 diabetic males with coronary heart disease when compared to healthy males showed significantly low levels of serum adiponectin (p=<0.001) and HDL-C (p=<0.001) and significantly high level of FBG (p=<0.001), HbA1c (p=<0.001), TC (p=<0.05), TG (p=<0.05) and LDL-C (p=<0.05). Serum adiponectin level showed a significant negative correlation with FBG (r = -0.332; p= 0.04), HbA1c (r = -0.818; p=<0.01) and TG (r = -0.640; p=<0.01) in type-2 diabetic men with coronary heart disease. Adiponectin showed a significant positive association with HDL-C in controls (r = 0.948; p=<0.01) and patients of type-2 diabetes with CHD (r = 0.650; p=<0.01). Conclusion: Serum adiponectin concentration is markedly decreased in patients of type-2 diabetes with coronary heart disease. Hypoadiponectinemia is related with deranged lipid profile, i.e., high TG and low HDL-C levels in type-2 diabetic men with CHD. Moreover, adiponectin is associated positively with HDL-C and negatively with HbA1c and TG levels in the studied population.Keywords: Adiponectin, Lipid profile, Type-2 diabetes mellitus, Coronary heart disease


Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047–53.

Nathan MD. Long-term complications of diabetes mellitus. N Eng J Med1993;328(23):1676–85.

Aqil S, Jaleel A, Jaleel F, Basir F. Comparison of adiponectin in ischemic heart disease versus ischemic stroke in diabetic patients. World Appl Sci J 2008;3(5):759–62.

Okrainec K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the developing world. Am Heart J 2004;148(1):7–15.

Takemura Y, Walsh K, Ouchi. N. Adiponectin and cardiovascular inflammatory responses. Cur Atheroscler Rep 2007;9(3):238–43.

Kadowaki T, Yamuchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26(3):439–51.

Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type-2 diabetic patients. Arterioscler Thromb Vascu Bio 2000;20(6):1595–9.

Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin molecular mechanism and potential therapeutic intervention. Clin Sci (Lond) 2008;114(5):361–74.

Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type-2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men. results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol 2006;48(7):1369–77.

Hashimoto N, Kanada J, Nakamura T, Horie A, Kurosawa H, Hashimoto T, et al. Association of hypoadiponectinemia in men with early onset of coronary heart disease and multiple coronary artery stenoses. Metabolism 2006;55(12):1653–7.

Wolfson N, Gawish D, Matas Z, Boaz M, Sharyorodsky M. Relation of Adinopectin to Glucose Tolerance Status, Adiposity and Cardiovascular Risk Factor. Exp Diabetes Res 2012:1–5.

Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006;114(7):623–9.

Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007;167(14):1510–7.

von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem 2006;52(5):853–9.

Lawlor DA, Smith GD, Ebrahim S, Thompson C, Sattar N. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005;90:5677–83.

Basati G, Pourfarzam M, Movahedian A, Samsamshariat SZ, Sarrafzadegan N. Reduced plasma adiponectin levels relative to oxidized low density lipoprotein and nitric oxide in coronary artery disease patients. Clinics (Sao paulo) 2011;66(7):1129–35.

Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Kihara S, Ouchi N. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. AtherosclerThrombVascu Bio 2003,23(1):85–9.

Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S, Hirose M, et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 2004;90:528–33.

Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, et al. Adiponectin an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 2006;27:2300–9.

Kojima S, Funahashi T, Sakamoto T, Miyamoto S, Soelima H, Hokamaki J. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 2003;89(6):667.

Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease Events Among Men with Type-2 Diabetes. Diabetes 2005;54(2):534–9.

Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. J Am Med Ass 2004;291:1730–7.

Dunajska K, Milewicz A, Jedrzejuk D, Szymczak J, Kuliczkowski W, Salomon P, et al. Plasma adiponectin concentration in relation to Severity of Coronary Atherosclerosis and Cardiovascular Risk Factors in Middle-Aged Men. Endocrine 2002;25:215–21.

Lindsay RS, Resnick HE, Zhu J, Tun ML, Howard BV, Zhang Y, et al. Adiponectin and coronary heart disease: the strong heart study. Atheroscler Thromb Vascu Biol 2005;25:e15–6.

Saely CH, Riseh L, Hoefle G, Rein P, Muendlein A, MarteT, et al. Low serum aAdiponectin is independently associated with both the metabolic syndrome and angiographicallydetermined coronary atherosclerosis. ClinChimActa 2007;383:97–102.

Rothenbacher D, Brenner H, Marz W, Koenig W. Adiponectin, Risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 2005;26(16):1640–6.

Masuda D, Sugimoto T, Tsujii K, Inagaki M, Nakatani K, Yuasa-Kawase M, Tsubakio-Yamamoto K, et al. Correlations of fasting serum apolipoprotein B-48 with coronary artery disease prevalence. Eur J Clin Inv 2012;42(9):992–9.

Karastergiou K, Mohamed-Ali V, Jehangiri M, Kaski J. Adiponectin for prediction of cardiovascular risk? Br J DiabeVascu Dis 2009;9(4):150–4.

Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with non-fasting triglycerides and risk of cardiovascular events in women. J Am Med Ass 2007;298(3):299–308.

Yamuchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, et al. Globular adiponectin protected ob/ob Mice from diabetes and ApoE-deficient Mice from atherosclerosis. J BioChem 2003;278:2461–8.

Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circulat Res 2005;96(12):1221–32.

Rasul S, Iihan A, Reiter MH, Baumgartner-Parzer S, Kautzky-willer A. Relations of adiponectin to levels of metabolic parameters and sexual hormones in elderly type-2 diabetic patients. Gender Med 2011;8(2):93–102.

Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Takayama S, Abe M, Katoh T, Ohtsuka N. Relationships between lipid profiles and metabolic syndrome, insulin resistance and serum high molecular adiponectin in Japanese Community-Dwelling adults. Lip Health Dis 2011;10(79):1–7.

Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, Didangelos TP, Yovos JG, Karamitsos DT. Effects of improving glycemic control with insulin on leptin, adiponectin, ghrelin and neuropeptide Y levels in patients with type-2 Diabetes Mellitus: a Pilot Study. Open Cardiovascu Med J 2011;5(6):136–47.

WuZ, Zhao S, Ye H. The beneficial effects of high-density lipoprotein on adipocytes may related to its anti-atherogenic properties. MedHypoth 2006;67(5):1195–9